Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy for gynecologic cancer.

M Markman1

  • 1Department of Hematology/Oncology, Cleveland Clinic Foundation, OH 44195.

Current Opinion in Oncology
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in Discounting Behavior and Brain Responses for Food and Money Reward.

eNeuro·2024
Same author

Apical hypertrophic cardiomyopathy: A case series at a Brazilian referral center with a maximal follow-up of 15 years.

Annales de cardiologie et d'angeiologie·2021
Same author

Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

European journal of gynaecological oncology·2018
Same author

Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.

Current oncology (Toronto, Ont.)·2018
Same author

Surgical intervention in relapsed ovarian cancer is beneficial: contra.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2011

Platinum-based chemotherapy is superior for ovarian cancer, with carboplatin equivalent to cisplatin. Effective treatments are emerging for endometrial, cervical, and gestational trophoblastic tumors, alongside fertility-sparing surgery for germ cell tumors.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Chemotherapy

Background:

  • Recent medical literature highlights advancements in gynecologic cancer chemotherapy.
  • Key studies focus on ovarian, endometrial, cervical, gestational trophoblastic, and germ cell tumors.

Purpose of the Study:

  • To review and synthesize recent findings on the chemotherapeutic management of various gynecologic cancers.
  • To assess the efficacy of different chemotherapy regimens and surgical approaches.

Main Methods:

  • Review of recently published medical literature on gynecologic cancer chemotherapy.
  • Analysis of clinical trial results and treatment outcomes.

Main Results:

  • Platinum-based chemotherapy demonstrates superiority in ovarian cancer treatment, with carboplatin showing equivalence to cisplatin.

Related Experiment Videos

  • Intraperitoneal chemotherapy shows activity in small-volume residual disease.
  • Cisplatin-based regimens achieve 40-50% response rates in endometrial cancer.
  • Etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine regimen is effective for high-risk gestational trophoblastic tumors.
  • Conservative surgery preserves fertility in germ cell tumors without compromising efficacy.

    • Conclusions:

    • Platinum-based chemotherapy remains a cornerstone for ovarian cancer management.
    • Emerging evidence supports various chemotherapy regimens and surgical strategies across gynecologic malignancies.
    • Further randomized trials are needed to confirm induction chemotherapy benefits in advanced cervical cancer.